Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 7/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298723 | 0.93 | CYP2C9 (0.71) | CYP2C9CYP3A4PIK3CABRAFCYP2C19 | |
| SCHEMBL299089 | 0.88 | CYP3A4 (0.64) | CYP2C9CYP3A4PIK3CABRAFCYP2C19 | |
| SCHEMBL288134 | 0.85 | PIK3CA (0.49) | CYP2C9CYP3A4PIK3CABRAFCYP2C19 | |
| SCHEMBL10246537 | 0.85 | PIK3CA (0.49) | CYP2C9CYP3A4PIK3CABRAFCYP2C19 | |
| SCHEMBL15667638 | 0.84 | CYP2C9 (0.60) | CYP2C9CYP3A4PIK3CABRAFCYP2C19 | |
| SCHEMBL15666835 | 0.84 | CYP2C9 (0.60) | CYP2C9CYP3A4PIK3CABRAFCYP2C19 | |
| SCHEMBL15667066 | 0.83 | CYP2C9 (0.57) | CYP2C9CYP3A4 | |
| SCHEMBL7878488 | 0.82 | CYP2C9 (0.76) | CYP2C9CYP3A4BRAFCYP2C19 | |
| SCHEMBL300106 | 0.82 | CYP2C9 (0.76) | CYP2C9CYP3A4BRAFCYP2C19 | |
| SCHEMBL12470946 | 0.81 | CYP2C9 (0.57) | CYP2C9CYP3A4PIK3CABRAFCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-2672967-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20170157120-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9624213-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CYP2C9 2176/4885CYP3A4 3611/4885PIK3CA 277/4885 |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, PRKACA, MAP3K13 | CYP2C9 4771/4885CYP3A4 4679/4885PIK3CA 80/4885 |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | CYP2C9 4771/4885CYP3A4 4679/4885PIK3CA 80/4885 |
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | CYP2C9 4771/4885CYP3A4 4679/4885PIK3CA 80/4885 |
| US-20170157120-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | CYP2C9 4771/4885CYP3A4 4679/4885PIK3CA 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.